CClinicalTrials.gg
CompletedNCT03985735Updated Jun 22, 2020

Characterisation of Gut Microbiota, Bispectral Index Data and Plasma Kynurenine in Patients Undergoing Video-assisted Thoracic Surgery

An observational study in Lung Cancer, sponsored by China Medical University, China. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-22.

Sponsored by China Medical University, China · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is a case-controlled observational trial. Sixty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data. Firstly, this study aims to characterise the gut and lung microbiota in patients with lung cancer treated with surgery. Secondly, it aims to evaluate microbiota and its influence on plasma kynurenine.

Read the detailed description

The study is a case-controlled observational trial. Sixty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data. Firstly, this study aims to characterise the gut and lung microbiota in patients with lung cancer treated with surgery. Secondly, it aims to evaluate microbiota and its influence on plasma kynurenine.

02

Conditions studied

  • Lung Cancer
03

In context

Lead sponsor

China Medical University, China is the lead sponsor of 93 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study is a case-controlled observational trial. Sixty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data.

Inclusion criteria

    1. ethnic Chinese;
    1. age, 18 to 75 years old;
    1. American Society of Anaesthesiologists (ASA) physical status I or II;
    1. required VATS for lung surgery and one lung ventilation .

Exclusion criteria

Exclusion Criteria:

  • Cognitive difficulties
  • Partial or complete gastrectomy
  • Previous esophageal surgery
  • Previous treated by radiotherapy or surgery
  • Inability to conform to the study's requirements
  • body mass index exceeding 30 kg/m2
  • Deprivation of a right to decide by an administrative or juridical entity
  • Ongoing participation or participation in another study \<1 month ago
  • preoperative Pittsburgh Sleep Quality Index global scores higher than 6
  • recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or traditional Chinese medicine
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Group good sleepers

    Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am). Sleeping time are more than six hours.

    Drug: General anesthesia

  • Group poor sleepers

    Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am). Sleeping time are less than two hours.

    Drug: General anesthesia

Interventions

  • DrugGeneral anesthesia

    For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium (0.05 mg/kg)and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.

06

What researchers measure

Primary outcomes

  1. lung and gut microbiota

    this study will characterise the lung and gut microbiota in 2 groups of 30 patients

    Time frame: from baseline to postoperative 72 hours

Secondary outcomes

  1. Bispectral index data

    this study will characterise the Bispectral index data in 2 groups of 30 patients

    Time frame: the first postoperative night

  2. plasma kynurenine concentrations

    this study will characterise the plasma kynurenine concentrations in 2 groups of 30 patients

    Time frame: baseline and the first postoperative night

07

Study locations

1 site
  • the First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03985735
Lead sponsor
China Medical University, China
Responsible party
Wen-fei Tan (Professor, China Medical University, China) — Principal investigator
First posted
Jun 14, 2019
Start date
Aug 1, 2019
Primary completion
Dec 31, 2019
Completion
Jan 20, 2020
Last update
Jun 22, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion